IP Library Granted Patent US 11,325,892
Granted Patent B2
US 11,325,892 · App. 16/422,519 · Granted May 10, 2022

Compounds and methods for treating cancer

Inventors: John A. Copland, III (Ponte Vedra Beach, FL); Han W. Tun (Jacksonville, FL); Thomas R. Caulfield (Jacksonville, FL); Christina Von Roemeling (Jacksonville, FL); Laura Ann Marlow (Jacksonville, FL)
Assignee: Mayo Foundation for Medical Education and Research
C07D295/192A61K31/44A61K31/495A61K31/496A61K45/06C07D211/64C07D211/66C07D213/64C07D213/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,325,892
App. No.
16/422,519
Granted
May 10, 2022
Kind
B2
Abstract

This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.

Claims (16)

1. A compound according to Formula (II):

or a pharmaceutically acceptable salt thereof,

wherein

R 1 is halo;

X is —(C═O)NR 4 —;

Y is

and

R 2 , R 3 , and R 4 are each independently H or an unsubstituted C 1-6 alkyl.

2. The compound of claim 1 , wherein the compound according to Formula (II) has the structure of Formula (IIa):

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein R 1 is Cl.

4. The compound of claim 1 , wherein R 4 is H.

5. The compound of claim 1 , wherein R 2 is H and R 3 is CH 3 .

6. The compound of claim 1 , wherein the compound according to Formula (II) is

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 , and a pharmaceutically acceptable carrier.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE FIRST ASSIGNOR'S NAME ON THE COVER SHEET PREVIOUSLY RECORDED AT REEL: 055429 FRAME: 0955. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 13, 2021
From: COPLAND, JOHN A., III; TUN, HAN W.; CAULFIELD, THOMAS R.; ROEMELING, CHRISTINA VON; MARLOW, LAURA ANN
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 056285/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2021
From: COPLAND, JOHN A.; TUN, HAN W.; CAULFIELD, THOMAS R.; ROEMELING, CHRISTINA VON; MARLOW, LAURA ANN
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 055429/0955 →
Continuity (3)
Continuation 15502301
Provisional Application 62034429 · Aug 7, 2014
Related Publication 20190345123A1 · Nov 14, 2019
Cited By (1)
US 12,286,413